Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05783323 · ClinicalTrials.gov registry record · Phase 2
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
A Phase 2 study of Cancer and Pediatric Cancer, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT05783323: Recruiting Phase 2 study of Cancer and Pediatric Cancer, sponsored by Children's Hospital of Philadelphia.
NCT05783323 is a Phase 2 study of Cancer and Pediatric Cancer that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 13 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05783323, a Phase 2 study of Cancer and Pediatric Cancer, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Primary Outcome
The primary endpoint is the complete pulmonary structural response rate to larotrectinib by modified Nies et al thyroid cancer response criteria.
Conditions Studied
Interventions
- DRUG Larotrectinib monotherapy
- RADIATION 131I therapy
Study Locations (5)
California
- University of California, San Francisco - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- MD Anderson Cancer Center - Houston
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-02-14 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
What NCT05783323 shows while recruiting
NCT05783323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Larotrectinib monotherapy is the first listed.
NCT05783323 lists 5 locations in 5 states (California, Pennsylvania, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05783323 about?
NCT05783323 is a clinical study titled "Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer". Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve ...
What is the current status of trial NCT05783323?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2024-02-14. Estimated completion is 2027-10-01.
What conditions does trial NCT05783323 study?
This clinical trial studies the following conditions: Cancer, Pediatric Cancer, Differentiated Thyroid Cancer, Cancer, Thyroid.
What interventions are being tested in trial NCT05783323?
The interventions under investigation include: Larotrectinib monotherapy (DRUG), 131I therapy (RADIATION).
Who is sponsoring clinical trial NCT05783323?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05783323 being conducted?
This trial has 5 study locations across California, Pennsylvania, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05783323's enrollment target sits among peer trials
13 592nd of 615 higher than 23 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI